Algernon Pharmaceuticals: The World's First Company to Investigate the Psychedelic Drug DMT as a Potential New Treatment for Stroke

Algernon Pharmaceuticals: The World’s First Company to Investigate the Psychedelic Drug DMT as a Potential New Treatment for Stroke

Algernon Pharmaceuticals is a publicly traded, Canadian clinical stage drug development company investigating multiple drugs for unmet medical needs with global market opportunities. Join CEO Christopher J. Moreau as he talks about the company’s unique drug development model including its anchor, ground-breaking clinical investigation of the psychedelic drug DMT as a possible new treatment for stroke.

Details

Main Stage

Track Format: Keynote


Date:	11/04/2022
Start Time:	12:50 pm
End Time:	13:20

Christopher Moreau

CEO, Algernon Pharmaceuticals

Mr. Moreau is the CEO of Algernon Pharmaceuticals Inc. and a member of the company’s board of directors. With over 30 years of executive management experience overall, including 15 years in CEO roles,…

Get Recordings Now!

Easily access the recordings for your favorite Wonderland sessions, allowing you to revisit the discussions and insights shared by our visionary speakers.